NATERA INC (NTRA) Stock Price, Quote, News and Overview
NASDAQ:NTRA - Nasdaq - US6323071042 - Common Stock - Currency: USD
NTRA Quote, Performance and Key Statistics
162.57
+2.47 (+1.54%)
The current stock price of NTRA is 162.57 USD. In the past month the price increased by 6.98%. In the past year, price increased by 54.4%.
NTRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.07 | 328.29B | ||
| AMGN | AMGEN INC | 13.1 | 146.27B | ||
| GILD | GILEAD SCIENCES INC | 12.68 | 122.21B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 110.44B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.36 | 59.13B | ||
| ARGX | ARGENX SE - ADR | 299.54 | 34.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.61B | ||
| ONC | BEIGENE LTD-ADR | 5.88 | 25.43B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.78B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.31B | ||
| BIIB | BIOGEN INC | 7.48 | 17.35B | ||
| UTHR | UNITED THERAPEUTICS CORP | 12.29 | 13.89B |
Related stock screener links
About NTRA
Company Profile
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. The company is headquartered in Austin, Texas and currently employs 4,424 full-time employees. The company went IPO on 2015-07-02. The firm's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. The company has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Company Info
NATERA INC
13011 Mccallen Pass, Building A Suite 100
Austin TEXAS 78753 US
CEO: Steve Chapman
Employees: 4424
Phone: 16502499090
NATERA INC / NTRA FAQ
What is the stock price of NATERA INC today?
The current stock price of NTRA is 162.57 USD. The price increased by 1.54% in the last trading session.
What is the ticker symbol for NATERA INC stock?
The exchange symbol of NATERA INC is NTRA and it is listed on the Nasdaq exchange.
On which exchange is NTRA stock listed?
NTRA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NATERA INC stock?
27 analysts have analysed NTRA and the average price target is 199.97 USD. This implies a price increase of 23.01% is expected in the next year compared to the current price of 162.57. Check the NATERA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NATERA INC worth?
NATERA INC (NTRA) has a market capitalization of 22.10B USD. This makes NTRA a Large Cap stock.
How many employees does NATERA INC have?
NATERA INC (NTRA) currently has 4424 employees.
What are the support and resistance levels for NATERA INC (NTRA) stock?
NATERA INC (NTRA) has a support level at 158.48 and a resistance level at 174. Check the full technical report for a detailed analysis of NTRA support and resistance levels.
Is NATERA INC (NTRA) expected to grow?
The Revenue of NATERA INC (NTRA) is expected to grow by 15.92% in the next year. Check the estimates tab for more information on the NTRA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NATERA INC (NTRA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NTRA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NTRA, evaluating the profitability, health, valuation and growth aspects
- NATERA INC (NTRA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NATERA INC (NTRA) Sales and EPS estimates to see what analysts future expectations are.
- NATERA INC (NTRA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NATERA INC (NTRA) Insider and Institutional Ownership to learn about the owners and their transactions.
- NATERA INC (NTRA) Stock Chart to make your own analysis
- NATERA INC (NTRA) Latest news and press-releases to stay up to date.
Does NATERA INC (NTRA) stock pay dividends?
NTRA does not pay a dividend.
When does NATERA INC (NTRA) report earnings?
NATERA INC (NTRA) will report earnings on 2025-05-08, after the market close.
What is the Price/Earnings (PE) ratio of NATERA INC (NTRA)?
NATERA INC (NTRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.53).
What is the Short Interest ratio of NATERA INC (NTRA) stock?
The outstanding short interest for NATERA INC (NTRA) is 4.62% of its float. Check the ownership tab for more information on the NTRA short interest.
NTRA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to NTRA. When comparing the yearly performance of all stocks, NTRA is one of the better performing stocks in the market, outperforming 92.28% of all stocks.
NTRA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to NTRA. NTRA has a great financial health rating, but its profitability evaluates not so good.
NTRA Financial Highlights
Over the last trailing twelve months NTRA reported a non-GAAP Earnings per Share(EPS) of -1.53. The EPS increased by 59.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.47% | ||
| ROE | -15.93% | ||
| Debt/Equity | 0.07 |
NTRA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to NTRA. The Buy consensus is the average rating of analysts ratings from 27 analysts.
For the next year, analysts expect an EPS growth of -43.9% and a revenue growth 15.92% for NTRA